Cancer Companion Guide

GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes. As their use expands globally, a critical question is emerging: Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health? This article reviews: The established link between obesity and cancer The biological mechanisms affected by GLP-1 therapy Human clinical trial data Observational cancer incidence studies Safety signals (including thyroid cancer) What remains unknown All claims below are supported by peer-reviewed sources. 1. Obesity and Cancer: Established Evidence The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1). Key cancers linked to obesity include: Colorectal Postmenopausal breast Endometrial Pancreatic Liver Mechanisms supported by human and transl...

Abstract Background:  Stage IV pancreatic ductal adenocarcinoma (PDAC) lacking actionable mutations has limited treatment options, with median overall survival (mOS) of 9–11 months using standard chemotherapy. Repurposed drugs (ivermectin, mebendazole) and hyperthermia show preclinical promise. This in silico randomized controlled trial (RCT) evaluates an integrative protocol combining ivermectin, mebendazole, hyperthermia, supplements, and lifestyle interventions versus standard-of-care (SOC) NALIRIFOX chemotherapy in non-BRCA-mutated stage IV PDAC. Methods:  A simulated two-arm RCT enrolled 200 patients with non-BRCA-mutated stage IV PDAC, randomized 1:1 to an experimental arm (ivermectin 1 mg/kg/day 3 days/week, mebendazole 500 mg twice daily, localized hyperthermia 42–43°C 3 sessions/week, supplements [vitamin C, vitamin D, curcumin, berberine], ketogenic diet, intermittent fasting, pancreatic enzymes) or control arm (NALIRIFOX). Primary endpoint was 12-month overall surv...

Executive Summary Over the past several years, repurposed antiparasitic drugs—particularly fenbendazole , mebendazole , and ivermectin —have attracted widespread attention in oncology communities. A publicly accessible compilation hosted by OneDayMD documents more than 500 anecdotal cancer cases reporting tumor regression, stabilization, or remission while using these agents, often in combination with conventional therapy or adjunctive supplements. This report does not treat these anecdotes as proof of efficacy. Instead, it applies pharmacovigilance logic, bias analysis, mechanistic plausibility review, and comparative survival context to assess whether this body of reports constitutes: Noise Wishful thinking Or a legitimate hypothesis-generating signal Conclusion: The dataset does not constitute mainstream clinical evidence. However, the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions. 1. ...

Abstract Background: Stage 4 prostate cancer has a 5-year survival rate of 37% with standard of care (SOC, e.g., androgen deprivation therapy [ADT], chemotherapy, Lu-177-PSMA-617). An optimized intervention combining repurposed drugs, supplements, diet/lifestyle, hyperthermia, and SOC components may improve outcomes. Methods : We simulated a double-blind RCT with 1,000 patients (500 per arm) with non-BRCA-mutated stage 4 prostate cancer (70% mHSPC, 30% mCRPC), comparing an integrative multimodal intervention arm (ivermectin 1.0–1.5 mg/kg/day (cycled 3 weeks on/1 off), mebendazole 500–1,500 mg/day (titrated), metformin 1,700 mg/day, vitamin C 1 g/kg IV 3 times/week, vitamin D 5,000 IU/day, curcumin 1,000 mg/day, low-glycemic Mediterranean diet, exercise, MBSR, hyperthermia [modulated electro-hyperthermia at 42°C for 60 minutes, 2–3 times weekly], plus ADT/Lu-177-PSMA-617) to a placebo arm with SOC. Primary endpoint was overall survival (OS); secondary endpoints included progression-fre...